215 Users Online
Duchenne Muscular Dystrophy market is segmented by Product Type that is NSAIDs, Corticosteroids and by therapy that is Mutation Suppression and Exon Skipping Approach.
Duchenne Muscular Dystrophy (DMD) is a muscle degeneration and is a genetic disorder which is X-linked recessive. However, it is also inherited from parents or caused due to a new mutation. There are various therapies and drugs to control DMD, however, there is still no cure for duchenne muscular dystrophy.
Major driving factors in the global duchenne muscular dystrophy market are the introduction of novel drugs and therapies, disease-modifying therapies, strong support from various companies for drug development and support from patient advocacy groups on the regulatory approval process. Moreover, mutation-specific therapies are likely to emerge as a major breakthrough in the duchenne muscular dystrophy treatment.
Drug developers are also focusing on developing new drugs and therapies targeting newborns, young infants and also the last-stage DMD patients. In the last few years, there has been rapid development in the duchenne muscular dystrophy therapeutics. However, there is still a large number of patients who are not able to benefit from therapies and drugs due to its high cost and lack of awareness.
Compared to the various products, corticosteroids are likely to emerge as the top-selling products during 2017-2026. By 2026 end, corticosteroids are projected to surpass US$ 9,000 million revenue. Various scientific research has found that compared to various products to treat duchenne muscular dystrophy, corticosteroids help in improving muscle strength for up to two to five years, however, long-term benefit of corticosteroids is still not clear.
Hospital pharmacies are likely to be the largest distribution channel between 2017 and 2026. Towards 2026 end, hospital pharmacies are projected to reach more than US$ 6,200 million revenue. Increasing number of people are being hospitalized for duchenne muscular dystrophy. Hence, drugs for duchenne muscular dystrophy are being sold on a large scale through hospital pharmacies. Also, governments of various countries are investing in the development of hospitals in urban as well as rural areas, this is also contributing to the growth of hospital pharmacies.
Among various therapies available for duchenne muscular dystrophy, mutation suppression is likely to be one of the highly preferred therapy for duchenne muscular dystrophy. By 2026 end, mutation suppression is projected to surpass US$ 6,000 million revenue.
Mutation suppression therapy in duchenne muscular dystrophy targets the specific mutation causing the muscular dystrophy. Also, nonsense mutation suppression therapy has offered potential benefit to a lot of people suffering from duchenne. However, several therapies are currently under clinical trials, while some are close to getting approval by the Food and Drugs Administration (FDA).
Europe is likely to emerge as one of the leading region in the global market for duchenne muscular dystrophy. Europe is projected to surpass US$ 4,900 million revenue by 2026 end. Meanwhile, North America followed by the Asia Pacific Excluding Japan (APEJ) are also likely to see a robust growth between 2017 and 2026.
Some of the major companies operating in the global market for duchenne muscular dystrophy include ITALFARMACO S.p.A., FibroGen, Inc., Summit Therapeutics plc, PTC Therapeutics, Santhera Pharmaceuticals, and Sarepta Therapeutics, Inc.